Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - FACC, Valneva (05/02/2024)

11.02.2024

FACC: The year 2024 marks the 35th anniversary of aerospace supplier FACC. Since its foundation in 1989, the company has grown from a small team of visionaries in the Fischer Ski & Tennis research department to a global player of the aerospace industry. All major aircraft manufacturers such as Airbus, Boeing, Embraer, Bombardier, COMAC, Collins, Rolls Royce and Pratt & Whitney place their trust in the know-how of the Austrian aviation specialist, which has enabled considerable weight savings and thus lower fuel consumption in flight operations with its lightweight construction innovations from the very beginning. The aerospace industry currently boasts full order books for years to come. FACC is also benefiting from this with a record order backlog of USD 5.8 billion. This growth is set to continue in the future – by 2042, demand for new aircraft in civil aviation will exceed 40,000. The next generation of aircraft will set new standards in terms of sustainability. The major goal of the international industry is to achieve a 75% cut in CO2 emissions by 2050 – lightweight construction solutions by FACC will make a significant contribution to achieving this goal.
FACC: weekly performance: 0.17%

Valneva: Austrian/French Valneva SE, a specialty vaccine company, announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million). The Company was awarded a tropical disease PRV in November 2023 following U.S. FDA approval of IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV). The company will invest proceeds from the sale of the PRV into its R&D projects, including the co-development of its Phase 3 vaccine candidate against Lyme disease, additional clinical trials for its chikungunya vaccine and the expansion of the Company’s clinical pipeline.
Valneva: weekly performance: 3.22%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/02/2024)


Partners









latest 21st Austria

21st Austria weekly - FACC, Valneva (05/02/2024)


11.02.2024, 2045 Zeichen



FACC: The year 2024 marks the 35th anniversary of aerospace supplier FACC. Since its foundation in 1989, the company has grown from a small team of visionaries in the Fischer Ski & Tennis research department to a global player of the aerospace industry. All major aircraft manufacturers such as Airbus, Boeing, Embraer, Bombardier, COMAC, Collins, Rolls Royce and Pratt & Whitney place their trust in the know-how of the Austrian aviation specialist, which has enabled considerable weight savings and thus lower fuel consumption in flight operations with its lightweight construction innovations from the very beginning. The aerospace industry currently boasts full order books for years to come. FACC is also benefiting from this with a record order backlog of USD 5.8 billion. This growth is set to continue in the future – by 2042, demand for new aircraft in civil aviation will exceed 40,000. The next generation of aircraft will set new standards in terms of sustainability. The major goal of the international industry is to achieve a 75% cut in CO2 emissions by 2050 – lightweight construction solutions by FACC will make a significant contribution to achieving this goal.
FACC: weekly performance: 0.17%

Valneva: Austrian/French Valneva SE, a specialty vaccine company, announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million). The Company was awarded a tropical disease PRV in November 2023 following U.S. FDA approval of IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV). The company will invest proceeds from the sale of the PRV into its R&D projects, including the co-development of its Phase 3 vaccine candidate against Lyme disease, additional clinical trials for its chikungunya vaccine and the expansion of the Company’s clinical pipeline.
Valneva: weekly performance: 3.22%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/02/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

BörseGeschichte Podcast: Wolfgang Aubrunner vor 10 Jahren zum ATX-25er




 

Bildnachweis

Aktien auf dem Radar:Amag, Polytec Group, DO&CO, RHI Magnesita, Semperit, Austriacard Holdings AG, Rosgix, AT&S, Lenzing, voestalpine, BTV AG, Hutter & Schrantz Stahlbau, Pierer Mobility, Porr, SBO, VIG, Addiko Bank, Rosenbauer, BKS Bank Stamm, Oberbank AG Stamm, SW Umwelttechnik, Flughafen Wien, Österreichische Post, Verbund, DAIMLER TRUCK HLD..., Fresenius Medical Care, Brenntag, Fresenius, Rheinmetall, Bayer, RWE.


Random Partner

Verbund
Verbund ist Österreichs führendes Stromunternehmen und einer der größten Stromerzeuger aus Wasserkraft in Europa. Mit Tochterunternehmen und Partnern ist Verbund von der Stromerzeugung über den Transport bis zum internationalen Handel und Vertrieb aktiv. Seit 1988 ist Verbund an der Börse.

>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten